About

Robert O. Heuckeroth, M.D., Ph.D., is a Professor of Pediatrics specializing in Gastroenterology, Hepatology, and Nutrition at the Children's Hospital of Philadelphia and the University of Pennsylvania. He holds the Irma and Norman Braman Endowed Chair for Research in GI Motility Disorders. His educational background includes a B.S. in Chemistry from the University of Maryland, and both his Ph.D. in Biochemistry and M.D. from Washington University School of Medicine in St. Louis. With over 20 years of clinical experience, he is a pediatric gastroenterologist dedicated to caring for children with complex bowel, liver, and pancreatic diseases. His research focuses on the molecular and cellular mechanisms that control the development of the enteric nervous system. His work involves molecular biology, genetics, live cell imaging, primary cell culture, epidemiology, physiology, biochemistry, stem cell biology, and regenerative medicine. He investigates the processes governing normal and abnormal development of the enteric nervous system, aiming to find new ways to prevent birth defects and repair damaged organs. His projects include defining the genetics of Hirschsprung disease and intestinal pseudoobstruction syndrome, identifying gene-environment interactions causing birth defects, understanding mechanisms to control enteric nervous system stem cell fate, developing regenerative medicine approaches for intestinal motility disorders, and establishing translational research programs to improve visualization of the enteric nervous system and bowel wall. His contributions are recognized through his leadership roles and ongoing research efforts in pediatric gastroenterology.

Research topics

• Biology
• Cell biology
• Medicine
• Neuroscience
• Internal medicine

Selected publications

• Clinical, manometric, genetic, and histologic associations in pediatric intestinal pseudo‐obstruction: A case series

  Journal of Pediatric Gastroenterology and Nutrition · 2026-01-01

  articleOpen accessSenior author

  OBJECTIVES: Pediatric intestinal pseudo-obstruction (PIPO) is a severe bowel motility disorder characterized by impaired propulsion of gastrointestinal contents without mechanical obstruction. PIPO encompasses congenital and acquired disorders, including neuropathies, myopathies, and mesenchymopathies. PIPO presents with abdominal distension, bilious vomiting, and severe constipation. Diagnosis is based on objective measures of neuromuscular dysfunction, dilated bowel on imaging, parenteral and/or enteral nutrition dependence, and genetic or metabolic testing. Antroduodenal manometry permits objective assessment of proximal bowel neuromuscular function. Genetic testing is increasingly valuable although causes of PIPO often remain incompletely defined. Understanding genotype-phenotype correlations is essential for clarifying disease mechanisms and guiding therapies. This study aimed to characterize the clinical and genetic profiles of children with PIPO, utilizing manometric data for subtype classification. METHODS: A retrospective chart review was conducted at a tertiary care pediatric medical center, with inclusion criteria of PIPO diagnosis, completed manometry testing, and genetic evaluation. RESULTS: Nineteen children met inclusion criteria. Antroduodenal manometry classified 59% as neuropathic, 35% as myopathic, and one with mixed neuropathic and myopathic dysfunction. Genetic testing revealed pathogenic ACTG2 mutations in all myopathic cases, while neuropathic PIPO exhibited more genetic variability. Histopathology was inconsistent and often nonspecific. Therapeutic approaches focused on nutritional support and promotility agents, with surgical intervention more common in myopathic cases. CONCLUSIONS: This study highlights the association of ACTG2 mutations with a myopathic phenotype, and genetic diversity in neuropathic PIPO, emphasizing the need for further research to improve phenotyping to enhance diagnosis and treatment.

  PublisherOA PDFDOI

• Antibiotic treatment reveals the contributions of the gut microbiome to CLN2 disease in the central and enteric nervous system

  Scientific Reports · 2026-04-25

  articleOpen access

  Abstract The Neuronal Ceroid Lipofuscinoses (NCLs) are fatal inherited lysosomal storage diseases, with pronounced neuron loss in the central nervous system (CNS). Gastrointestinal issues are frequently reported by people with NCLs, although mechanisms underlying these symptoms are poorly understood. We recently demonstrated degeneration occurs within the enteric nervous system (ENS) in several NCLs. Given that the gut microbiome has been shown to be altered a CLN2 mouse model ( Tpp1 R207X/R207X ) and may potentially influence both CNS and ENS pathology, we investigated the long-term impact of modulating the gut microbiome in these mice. This was done by administering a VNAM antibiotic cocktail (vancomycin, neomycin, ampicillin, and metronidazole) for 1-week post-weaning, examining its effects at disease endstage. While VNAM treatment markedly altered the gut microbiome and caused significant loss of enteric neurons in wildtype mice, it did not exacerbate key pathological parameters in either bowel or brain of Tpp1 R207X/R207X mice. These included histomorphometric changes in the small intestine and neurodegeneration of enteric neurons, or CNS neuropathology. However, we did find evidence for moderate protective effects of VNAM upon enteric neurons in the ileum, and upon CNS microglia, but all other pathologies were unaltered in Tpp1 R207X/R207X mice. These findings suggest that intestinal and ENS pathology is primarily driven by TPP1-deficiency rather than changes in the gut microbiome. Indeed, these alterations to the gut microbiome may occur secondary to the impact of CLN2 disease upon the bowel.

  PublisherDOI

• International Forum on Visceral Myopathy 2024: Advances in the Knowledge of the Disease

  Neurogastroenterology & Motility · 2026-04-01

  articleOpen access

  BACKGROUND: Visceral myopathy (VSCM) is an ultra-rare life-threatening condition characterized by severe impairment of gastrointestinal (GI), genitourinary, and uterine smooth muscle. This disorder represents a significant clinical challenge due to variable presentation and the lack of standardized diagnostic and therapeutic protocols. METHODS: To discuss advances in the field, scientists and clinicians with a special interest in VSCM met in Arenzano, Genova, Italy in October 2024 for the second International Forum on Visceral Myopathy 2024 (IFVM2024) (https://ifvm2024.ge.ibf.cnr.it/). KEY RESULTS: As in the previous edition of the event (https://poic-e-dintorni.org/efvm-2022/), attendees included clinicians and researchers from around the world who study this disease, representatives from support organizations, patients affected by VSCM and their families, and companies that co-funded the event. The present manuscript aims to summarize knowledge shared during the IFVM2024 conference, thus providing an updated state-of-the-art summary of VSCM biology and disease management. CONCLUSIONS: Here, we pay particular attention to the epidemiology of the disease, histopathology, genetics, novel treatments, advances in molecular and cell biology, experimental models, and the lived experiences and impact of this disorder on families.

  PublisherDOI

• Treatment of dysphagia associated pathologies in CLN3 deficient mice via gene therapy

  Molecular Genetics and Metabolism · 2025-01-30

  article
  PublisherDOI

• 663: A ROLE FOR LINGO2 IN ENTERIC NEURON-MEDIATED INTESTINAL REPAIR

  Gastroenterology · 2025-05-01

  article
  PublisherDOI

• Genome-wide association meta-analysis identifies 126 novel loci for diverticular disease and implicates connective tissue and colonic motility

  medRxiv · 2025-03-28 · 2 citations

  preprintOpen access

  Diverticular disease is a common and morbid complex phenotype influenced by both innate and environmental risk factors. We performed the largest genome-wide association study meta-analysis for diverticular disease, identifying 126 novel loci. Employing multiple downstream analytic strategies, including tissue and pathway enrichment, statistical fine-mapping, allele-specific expression, protein quantitative trait loci and drug-target investigations, and linkage disequilibrium score regression, we prioritized causal genes and produced several lines of evidence linking diverticular disease to connective tissue biology and colonic motility. We substantiated these findings by integrating single-cell RNA sequencing data, showing that prioritized diverticular disease-associated genes are enriched for expression in colonic smooth muscle, fibroblasts, and interstitial cells of Cajal. In quantitative analysis of surgical specimens, we found a substantial reduction in the density of elastin present in the sigmoid colon in severe diverticulitis.

  PublisherDOI

• Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in mice

  Acta Neuropathologica Communications · 2025-12-22 · 1 citations

  articleOpen access

  Severe gastrointestinal (GI) symptoms occur in people with CLN3 disease, a neurodegenerative disorder. If left untreated these GI symptoms compromise life quality and may contribute to death. We hypothesized GI symptoms in CLN3 disease are at least partially due to neurodegeneration in the enteric nervous system (ENS), the master regulator of bowel function. We examined the integrity of the ENS in human CLN3 autopsy small bowel and colon, and in CLN3 deficient (Cln3Δex7/8) mice. We performed detailed immunohistological analyses of enteric neurons and glia and assessed bowel transit times at multiple disease stages. We then tested the therapeutic potential of neonatal intravenous gene therapy (AAV9.hCLN3) to prevent bowel phenotypes in Cln3Δex7/8 mice. Human CLN3 bowel displayed a profound loss of enteric neurons and their neurites, with pathological effects upon enteric glia. Cln3Δex7/8 mice had normal appearing ENS at 1 month of age, but then experienced progressive loss of both enteric neurons and glia accompanied by marked bowel distention, resembling the human CLN3 phenotype. Degenerative changes in Cln3Δex7/8 mouse enteric neurons and glia were largely prevented by systemic neonatal delivery of AAV9.hCLN3 gene therapy, preventing bowel distention at disease endstage. Our findings demonstrate that CLN3 deficiency profoundly damages enteric neurons and glia in both murine and human CLN3 disease, contributing to GI dysfunction. This study provides preclinical evidence that systemic gene therapy may effectively treat multiple aspects of bowel pathology, expanding the therapeutic landscape beyond the CNS.

  PublisherOA PDFDOI

• Additional file 1 of Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in mice

  Figshare · 2025-01-01

  articleOpen access

  Supplementary Material 1

  PublisherDOI

• 1044: DIET MANIPULATION AND SELECTIVE MICROBE EDITING AMELIORATES LETHAL ENTEROCOLITIS IN HIRSCHSPRUNG DISEASE

  Gastroenterology · 2025-05-01

  articleSenior author
  PublisherDOI

• Rapid cyclic stretching of cultured human visceral smooth muscle cells promotes a synthetic, proinflammatory phenotype

  JCI Insight · 2025-09-16 · 2 citations

  articleOpen access

  Bowel smooth muscle experiences mechanical stress constantly during normal function and pathologic mechanical stressors in disease states. We tested the hypothesis that pathologic mechanical stress could alter transcription to induce smooth muscle phenotypic class switching. To test this hypothesis, primary human intestinal smooth muscle cells (HISMCs), seeded on electrospun aligned poly-ε-caprolactone nano-fibrous scaffolds, were subjected to pathologic, high-frequency (1 Hz) uniaxial 3% cyclic stretch (loaded) or kept unloaded in culture for 6 hours. RNA-Seq, quantitative PCR (qPCR), and quantitative IHC defined loading-induced changes in gene expression. NicheNet predicted how differentially expressed genes might affect HISMCs and other bowel cells. These studies show loading induced differential expression of 4,537 HISMC genes. Loaded HISMCs had a less contractile phenotype, with increased expression of synthetic SMC genes, proinflammatory cytokines, and altered expression of axon guidance molecules, growth factors, and morphogens. Many differentially expressed genes encode secreted ligands that could act cell autonomously on smooth muscle and on other cells in the bowel wall. These data show that HISMCs undergo remarkably rapid phenotypic plasticity in response to mechanical stress that may convert contractile HISMCs into proliferative fibroblast-like cells or proinflammatory cells. These mechanical stress-induced changes in HISMC gene expression may be relevant for human bowel disease.

  PublisherOA PDFDOI

Recent grants

• Biochemical and cellular mechanisms linking actin mutations to visceral myopathy

  NIH · $3.5M · 2021–2026

• NIH Grant R01DK057038

  NIH · $2.0M · 2011

• Molecular and Functional Analysis of Hirschsprung Defects in Humans and Mouse

  NIH · $2.8M · 2020–2025

• NIH Grant R01DK064592

  NIH · $2.5M · 2009

• NIH Grant R21DK068371

  NIH · $306k · 2006

Frequent coauthors

• Sabine Schneider

  University of Pennsylvania

  52 shared

• Christina M. Wright

  Children's Hospital of Philadelphia

  48 shared

• S. Hashmi

  37 shared

• Jeffrey Milbrandt

  31 shared

• Deepika R. Kothakapa

  Children's Hospital of Philadelphia

  27 shared

• Marina Avetisyan

  25 shared

• Ceron RH

  Children's Hospital of Philadelphia

  19 shared

• Ellen Merrick Schill

  Washington University in St. Louis

  18 shared

Education

• M.D. Ph.D.

  Washington University School of Medicine in St. Louis

  1990

• B.S.

  University of Maryland, College Park

  1983

Awards & honors

• Irma and Norman Braman Endowed Chair for Research in GI Moti…